IP Library Granted Patent US 12678482
Granted Patent B2
US 12678482 · App. 17/317,152 · Granted Jul 14, 2026

Methods and compositions for treating chronic lung diseases

Inventors: Norman Barton (Lexington, MA); Alexandra Mangili (Lexington, MA)
Assignee: OAK HILL BIO LIMITED
A61K38/1754A61K38/30A61P11/00A61P25/00A61P27/00A61K9/0019A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678482
App. No.
17/317,152
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention provides, among other things, methods and compositions for treating Chronic Lung Disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof.

Claims (6)

1 . A method of treating Chronic Lung Disease comprising administering to a premature infant a composition comprising an equimolar complex of insulin-like growth factor-I (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), wherein the complex is administered by continuous intravenous infusion at a dosage of complex of about 400 micrograms/kg/24 hours from birth to post-menstrual age of about 24 to 34 weeks.

2 . The method of claim 1 , wherein the infant was prematurely born by at least 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, or 3 months.

3 . The method of claim 1 , wherein the complex is administered from the time of birth up to PMA of about 28 to 32 weeks.

4 . The method of claim 1 , wherein the complex is administered from the time of birth up to PMA of about 29 weeks plus 6 days.

5 . The method of claim 1 , wherein the IGF-1, or IGFBP-3 or both are recombinantly produced.

6 . The method of claim 1 , wherein Chronic Lung Disease is Bronchopulmonary dysplasia (BPD).